Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: A randomized, double-blind trial

Human Psychopharmacology

Volumn 25, Issue 7-8, 2010, Pages 560-565

  Mohammadi, Mohammad Reza ^a   Kazemi, Mohammad Reza ^a   Zia, Ebtehal ^a   Rezazadeh, Shams Ali ^b   Tabrizi, Mina ^c   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Institute of Medicinal Plants Iran   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

amantadine; attention deficit hyperactivity disorder; methylphenidate

Indexed keywords

AMANTADINE; METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EMOTIONAL DISORDER; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TEACHER AND PARENT ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADOLESCENT; AMANTADINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 79951745539     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1154     Document Type: Article

References (21)

1. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H,. 2003. Selegiline in the treatment of attention-deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27: 841-845. (Pubitemid 36966767)
2. Akhondzadeh S, Mohammadi MR, Khademi M,. 2004. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 8 (4): 9.
3. American Psychiatric Association. 2000. American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders DSM IV-TR, 4th edn (Text Revision). American Psychiatric Press: Washington, DC.
4. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S,. 2008. Modafinil as a treatment for attention-deficit/ hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32: 145-149.
5. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A,. 2004. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13: 102-116.
6. Curatolo P, Paloscia C, D'Agati E, Moavero R, Pasini A,. 2009. The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 13: 299-304.
7. Douglas RG,. 1990. Drug therapy. Prophylaxis and treatment of influenza. N Engl J Med 322: 443-450.
8. Dopheide JA, Pliszka SR,. 2009. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29: 656-679.
9. DuPaul G, Power T, Anastopoulos A, Reid R,. 1998. ADHD Rating Scale-IV. Guilford: New York.
10. Donfrancesco R, Calderoni D, Vitiello B,. 2007. Open-label amantadine in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17: 657-663. (Pubitemid 350058978)
11. Glezen WP,. 1993. Indications for amantadine in otherwise healthy children. Pediatr Infect Dis J 12: 106. (Pubitemid 23020194)
12. Ghanizadeh A, Mohammadi MR, Yazdanshenas A,. 2006. Psychometric properties of the Farsi translation of the Kiddie Schedule for Affective Disorders and Schizophrenia-present and lifetime version. BMC Psychiatry 15 (6): 10.
13. Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S,. 2009. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168: 234-237.
14. Kornhuber J, Weller M, Shoppmeyer K, Riedereer P,. 1994. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 43 (Suppl.): 91-104. (Pubitemid 24362365)
15. Kampman KM, Volpicelli JR, Alterman AI, Cornish J, O'Brien CP,. 2000. Amantadine in the treatment of cocaine dependent patients with severe withdrawal symptoms. Am J Psychiatry 157: 2052-2054.
16. King BH, Wright DM, Snape M, Dourish CT,. 2001. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry 40: 654-657. (Pubitemid 32473378)
17. Mattes J,. 1980. A pilot trial of amantadine in hyperactive children. Psychopharmacology 16: 67-69.
18. Mohammadi MR, Akhondzadeh S,. 2007. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Exp Rev Neurotrapeutics 7: 195-201. (Pubitemid 46434167)
19. Moresco RM, Volonte MA, Messa C, et al. 2002. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: A PET-[(11)C] raclopride study. J Neural Transm 109: 1265-1274.
20. Noorbala AA, Akhondzadeh S,. 2006. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Arch Iranian Med 9: 374-380. (Pubitemid 44803582)
21. Zarinara AR, Mohammadi MR, Hazrati N, et al. 2010. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol (in press). DOI: 10.1002/hup.1148